PCa incidence rates declined in the last decade [2], in part due to decreased screening since the US Preventive Services Task Force recommended against the use of prostate-specific antigen (PSA) testing in 2008 [3] and 2012 [4], but racial disparities in PCa persist. The gene discussed is KLK3; the disease is posterior cortical atrophy.